Preclinical Development – Chemical
2019 PharmSci 360
Ruth will present lessons and case studies gained from >20 years’ experience in the pharmaceutical industry focusing on attrition, prediction and nonclinical to clinical concordance. One of the most ‘translatable’ preclinical screens is hERG, and great progress has been made in reducing attrition due to cardiovascular liability with the advent of hERG screening. Building on this, other translatable screens are needed to allow chemical liabilities to be eliminated early in discovery while there are still options in chemistry. Equally important is a thorough understanding of potential target-related risks and their likelihood of occurrence. Failures in drug discovery and development should drive us to take a longer term, strategic approach: new technologies such as micro physiological systems (MPS), artificial intelligence and big data all offer opportunities to do things differently. But are we ready for change? These issues and potential solutions will be presented for discussion.